Using 3D organoids to study blood cancer and treatment responses
Novel 3D Hematological Malignancy Organoid Platform to Study Disease Biology and Perform Chemosensitivity Assays for Patient-Specific Care
This study is testing a new way to grow mini versions of tumors from bone marrow to see how well different chemotherapy treatments work for people with blood cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Winston-Salem, North Carolina) |
| Trial ID | NCT03890614 on ClinicalTrials.gov |
What this trial studies
This project aims to utilize a novel 3D organoid technique to analyze chemosensitivity in patients with hematologic malignancies. By creating organoids from bone marrow aspirates, the study will evaluate how these organoids respond to various chemotherapy combinations, providing insights into personalized treatment options. The research will also assess tumor markers and genetic characteristics to better understand tumor biology and resistance mechanisms. The ultimate goal is to validate the predictive value of these organoid responses against historical patient treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates include patients with suspected or confirmed hematologic malignancies who are undergoing a bone marrow biopsy.
Not a fit: Patients who do not have a hematologic malignancy or are not undergoing a bone marrow biopsy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for patients with hematologic malignancies.
How similar studies have performed: While the use of 3D organoids is a relatively novel approach, similar studies have shown promise in other cancer types, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with suspected or confirmed hematologic malignancy undergoing a bone marrow biopsy as part of their care. * The ability to understand and willingness to sign an IRB approved informed consent document.
Where this trial is running
Winston-Salem, North Carolina
- Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Timothy Pardee, MD, PhD — Wake Forest University Health Sciences
- Study coordinator: Study Coordinator
- Email: Holly.Maize@Advocatehealth.org
- Phone: 3367165772
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.